Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies.

CNS drugs - 1 Apr 2026

Dzamko Nicolas

Abstract excerpt

Parkinson's disease (PD) is a common neurodegenerative movement disorder that currently has no disease-modifying therapies. Over the past two decades, there has been a substantial acceleration in the knowledge of how genetics underlies PD risk. This has given rise to pathological protein targets that can be therapeutically targeted. In particular, there is compelling evidence for developing therapeutic strategies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Antiparkinson Agents
Share to Glucosylceramidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Mutation

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 41703390
DOI: 10.1007/s40263-026-01275-y
PMCID: PMC12988910

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies.PMID 41703390Read ↗

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.Semantic proximity Read ↗

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Semantic proximity Read ↗

Recent advances in targeting LRRK2 for Parkinson's disease treatment.Semantic proximity Read ↗

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.Semantic proximity Read ↗

LRRK2 and Proteostasis in Parkinson's Disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.Semantic proximity Read ↗

Development of targeted therapies for Parkinson's disease and related synucleinopathies.Semantic proximity Read ↗

Parkinson's disease: etiopathogenesis and treatment.Semantic proximity Read ↗

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read ↗

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.